29.10.03 · psychology / therapy-treatment

Biological treatments: pharmacotherapy mechanisms, ECT, TMS, psychedelic-assisted therapy

stub3 tiersLean: nonepending prereqs

Anchor (Master): Stahl, S. M. — Stahl's Essential Psychopharmacology, 5th ed. (2021)

Intuition Beginner

Psychiatric medications act on brain chemistry. Antidepressants like Prozac (an SSRI) boost serotonin by blocking its reuptake, easing depression and anxiety over several weeks. Antipsychotics block dopamine receptors, quieting the hallucinations and delusions of schizophrenia. Lithium, a simple salt, stabilizes mood in bipolar disorder, though its mechanism remains only partly understood.

Stimulants like Ritalin calm people with ADHD by raising dopamine and norepinephrine in the prefrontal cortex. Electroconvulsive therapy (ECT) passes a brief current through the brain to trigger a controlled seizure. It sounds frightening, but with modern anesthesia it is safe and remains the most effective treatment for severe, treatment-resistant depression.

Transcranial magnetic stimulation (TMS) uses magnetic pulses to stimulate specific brain regions without any seizure. The newest frontier is psychedelic-assisted therapy: psilocybin (from mushrooms) and MDMA are showing striking results for depression and PTSD in clinical trials.

Why "biological" treatments?

These interventions share a common thread — they act directly on the brain's physical machinery rather than primarily through conversation. A pill changes neurotransmitter levels. A magnetic pulse changes neural firing. A psychedelic reorganizes brain activity. None of them is a magic fix, and most work best paired with psychotherapy and social support. The label "biological" names the entry point, not the whole story of recovery.

Visual Beginner

The table groups the major biological treatments by what they act on and what they are best known for. Most are not interchangeable — each fits specific disorders and situations.

Treatment	Acts on	Strongest use	Notable drawback
SSRIs	Serotonin reuptake	Depression, anxiety	Weeks to work; sexual side effects
Antipsychotics	Dopamine D2 receptors	Schizophrenia, mania	Weight gain, movement effects
Lithium	Multiple targets (unclear)	Bipolar mood swings	Narrow safety margin
Stimulants	Dopamine / norepinephrine	ADHD	Appetite loss, insomnia
ECT	Seizure under anesthesia	Severe resistant depression	Memory disruption
TMS	Magnetic pulses to cortex	Resistant depression	Many sessions; modest effect
Psychedelics	5-HT2A receptors	Depression, PTSD (trials)	Experimental; requires therapy

The chart matters because it ranks interventions by what they actually deliver, not by reputation. ECT's high response rate for severe depression is often unknown outside psychiatry, and ketamine's speed (hours, not weeks) challenges the old assumption that every antidepressant must act slowly.

Worked example Beginner

Robert is 58. After a heart attack and a divorce in the same year, he slid into a depression that did not lift. His doctor tried an SSRI, then another, then an SNRI. None moved his mood, his sleep, or his wish to stay in bed. He lost 20 pounds. He told his daughter he was "done."

This is treatment-resistant depression — depression that has not responded to at least two adequate medication trials. It is common, not rare. The doctor presents three evidence-based options beyond another pill.

The first is a different drug mechanism: bupropion or an atypical antidepressant. The second is transcranial magnetic stimulation, a daily outpatient treatment over several weeks that requires no anesthesia. The third is electroconvulsive therapy, which works faster and more powerfully but carries some memory side effects.

Robert's daughter asks which is "best." The honest answer: each helps some people and not others, and the choice weighs speed, side effects, and access. For a man with weight loss and hopelessness, ECT's speed and potency made it the leading option. After eight sessions he ate a full meal for the first time in months. He did not feel "cured," but he felt alive enough to keep going — the precondition for every other treatment to work.

Check your understanding Beginner

Exercise (easy, multiple choice).

An SSRI like fluoxetine (Prozac) is thought to relieve depression mainly by doing what?

A. Blocking dopamine receptors in the mesolimbic pathway B. Blocking the reuptake of serotonin so more remains in the synapse C. Triggering a seizure under anesthesia D. Directly destroying the serotonin transporter

Hint

The name "SSRI" spells out the mechanism: Selective Serotonin Reuptake Inhibitor.

Answer

Option B. Blocking the reuptake of serotonin so more remains in the synapse.

SSRIs bind the serotonin transporter and stop it from clearing serotonin out of the synaptic cleft. Serotonin then lingers and activates the postsynaptic receptor more strongly. Mood improvement lags the chemistry by weeks, which is part of why the mechanism cannot be a simple "more serotonin, instant relief."

Exercise (easy, multiple choice).

Why do stimulants like methylphenidate (Ritalin) "calm" many people with ADHD rather than making them more hyper?

A. People with ADHD are immune to stimulants B. Stimulants suppress the prefrontal cortex entirely C. They raise dopamine and norepinephrine, strengthening prefrontal regulation D. They act as sedatives at the doses used

Hint

The prefrontal cortex needs dopamine and norepinephrine to sustain attention and inhibit impulses.

Answer

Option C. They raise dopamine and norepinephrine, strengthening prefrontal regulation.

In ADHD the prefrontal cortex is under-stimulated by these neurotransmitters. Raising their levels improves attention, planning, and impulse control. What looks "paradoxical" — a stimulant calming someone — is just the cortex finally getting the signaling it needs.

Exercise (medium, multiple choice).

Which statement about electroconvulsive therapy (ECT) is accurate?

A. It is an outdated treatment no longer used in modern medicine B. It is among the most effective treatments for severe, treatment-resistant depression C. It works by selectively destroying dopamine neurons D. It carries no cognitive side effects at all

Hint

ECT is done under anesthesia and muscle relaxant today, and it remains in use precisely because of its efficacy in hard cases.

Answer

Option B. It is among the most effective treatments for severe, treatment-resistant depression.

Modern ECT uses general anesthesia and a muscle relaxant, with a controlled electrical dose. It achieves high response rates where medications have failed, especially in life-threatening depression (refusal to eat, high suicide risk). The cost is real cognitive side effects — particularly retrograde memory around the treatment period — which are weighed against the severity of the illness.

Formal definition Intermediate+

Pharmacokinetics and pharmacodynamics

A drug's effect splits into two halves. Pharmacokinetics is what the body does to the drug: absorption, distribution, metabolism (chiefly hepatic, via the cytochrome P450 family), and excretion. Pharmacodynamics is what the drug does to the body: which receptors it binds, how strongly, and what downstream signaling results.

Receptor binding is described by two quantities. Affinity is how tightly a drug attaches to its receptor. Efficacy (or intrinsic activity) is the strength of the response the bound drug produces. These two axes generate the main functional classes:

Agonists bind and fully activate the receptor.
Antagonists bind but produce no activation; they block endogenous transmitter or an agonist from acting.
Partial agonists bind and activate, but to a submaximal degree — producing a ceiling effect that can either stimulate an underactive system or dampen an overactive one (aripiprazole at D2 is the canonical example).
Positive allosteric modulators bind a site distinct from the transmitter's and amplify the transmitter's effect without directly activating the receptor (benzodiazepines at the GABA-A complex).

A single drug rarely hits one target cleanly. Most psychiatric drugs act at several receptors, and the side-effect profile is often the shadow of those off-target actions.

Antidepressants

Synaptic monoamine level \propto \frac{release rate}{reuptake + metabolism}

The major antidepressant classes differ by which term of this ratio they suppress.

SSRIs (fluoxetine/Prozac, sertraline/Zoloft, escitalopram/Lexapro) block the serotonin transporter. Onset of clinical benefit is 4-6 weeks despite an acute rise in synaptic serotonin. Common side effects: nausea, gastrointestinal upset, sexual dysfunction.
SNRIs (venlafaxine, duloxetine) block reuptake of both serotonin and norepinephrine, useful when an SSRI has failed or when pain symptoms co-occur.
Atypicals. Bupropion (Wellbutrin) acts on dopamine and norepinephrine, lacks the sexual side effects of SSRIs, and lowers seizure threshold. Mirtazapine antagonizes 5-HT and alpha-2 receptors; it is sedating and stimulates appetite.
Tricyclics (TCAs) are older, block monoamine reuptake broadly, and carry heavy anticholinergic and cardiac loadings — dangerous in overdose.
MAOIs inhibit monoamine oxidase, the enzyme that breaks down monoamines. Their dietary restriction (tyramine-rich foods can trigger a hypertensive crisis) makes them third-line.

Antipsychotics

Typical / first-generation (haloperidol, chlorpromazine) are dopamine D2 antagonists. They suppress positive symptoms (hallucinations, delusions) effectively but carry a high burden of extrapyramidal symptoms (EPS): parkinsonism, akathisia, dystonia, and the often irreversible tardive dyskinesia.
Atypical / second-generation (risperidone, olanzapine, quetiapine, aripiprazole, clozapine) combine D2 antagonism with 5-HT2A antagonism (aripiprazole is a D2 partial agonist). They lower the EPS burden at the cost of metabolic syndrome — weight gain, dyslipidemia, insulin resistance. Clozapine is the gold standard for treatment-resistant schizophrenia but requires blood monitoring for the rare but dangerous agranulocytosis.

Mood stabilizers

Lithium remains unmatched for bipolar disorder. It has a narrow therapeutic window: blood levels must sit between roughly 0.6 and 1.2 mEq/L. Monitoring covers serum level, thyroid function, and renal function. Its most distinctive property is an anti-suicide effect that outpaces its mood-stabilizing action. Its mechanism is genuinely unsettled — plausible targets include inositol depletion, GSK-3 inhibition, and neurotrophic signaling.

The anticonvulsants valproate, lamotrigine, and carbamazepine are alternative mood stabilizers, with lamotrigine favored for the depressed pole of bipolar illness.

Anxiolytics and ADHD medications

Benzodiazepines (diazepam, alprazolam, lorazepam) are GABA-A positive allosteric modulators. They act fast but carry tolerance, dependence, and a withdrawal syndrome that can be dangerous. Buspirone, a 5-HT1A partial agonist, has delayed onset but no dependence liability.

Stimulants (methylphenidate/Ritalin, amphetamines/Adderall) raise synaptic dopamine and norepinephrine and are controlled substances. Side effects include appetite suppression, insomnia, and cardiovascular effects. The non-stimulants atomoxetine (a norepinephrine reuptake inhibitor) and guanfacine (an alpha-2 agonist) are alternatives, especially when stimulant misuse is a concern.

Somatic (non-pharmacological) treatments

Electroconvulsive therapy (ECT). Indications: severe depression, catatonia, treatment-resistant depression, life-threatening depression (refusal to eat, acute suicide risk). Procedure: general anesthesia plus a muscle relaxant, electrical induction of a seizure, 6-12 sessions over 2-4 weeks, with unilateral or bilateral electrode placement. Mechanism is unknown; candidates include neuroplasticity, BDNF upregulation, GABA upregulation, and neurogenesis. Chief side effect is memory loss, especially retrograde autobiographical memory for bilateral placement; cognitive effects are usually transient.

Transcranial magnetic stimulation (TMS). Repetitive TMS (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) is approved for treatment-resistant depression, delivered over 30-36 sessions with modest effect. Theta burst stimulation delivers the same dose faster. Deep TMS reaches deeper structures. Seizure risk is minimal. Vagus nerve stimulation (VNS) uses an implanted device and is approved for chronic recurrent depression that has not responded to other treatments.

Key mechanism: the acute-chronic gap and what it reveals Intermediate+

The SSRI puzzle

The most theoretically important fact about SSRIs is the mismatch between their pharmacodynamic time course and their clinical time course. Synaptic serotonin rises within hours of the first dose. Mood improves over weeks. If the antidepressant effect were simply "more serotonin in the synapse," patients should feel better on day one. They do not.

This gap has driven every modern account of antidepressant action toward downstream adaptation rather than acute monoamine elevation. The leading candidate mechanisms:

5-HT1A receptor desensitization. Somatodendritic autoreceptors that initially brake serotonin release gradually downregulate, releasing the brake over weeks.
BDNF upregulation and hippocampal neurogenesis. Chronic (not acute) antidepressant exposure raises brain-derived neurotrophic factor and increases the birth of new neurons in the dentate gyrus. Neurogenesis blockade appears to block antidepressant response in animal models.
Anti-inflammatory effects. Chronic treatment reduces markers of neuroinflammation, linking antidepressants to the inflammation hypothesis of depression (some depressed patients show elevated cytokines, and anti-cytokine treatments such as ustekinumab show antidepressant effects in inflammatory subgroups).

The pattern is consistent across ECT, TMS, and ketamine too: the rapid pharmacological event and the slower therapeutic effect sit on different timescales, which is strong evidence that the therapeutic mechanism is a slow adaptive process, not the acute receptor action itself.

Antipsychotics: the D2 occupancy window

Typical antipsychotics follow a remarkably tight dose-occupancy rule. Below roughly 60% D2 receptor occupancy they tend to be ineffective; above 80% they tend to produce extrapyramidal symptoms. The therapeutic window is the band in between, and clozapine's efficacy in treatment-resistant cases sits outside this rule — a hint that pure D2 blockade is not the whole story of antipsychotic action.

Lithium: an effective drug with no settled target

Lithium is the field's most stubborn mechanistic puzzle. A monovalent cation with no single high-affinity receptor has, for over 70 years, remained the most effective single treatment for bipolar disorder and one of the few drugs with a documented anti-suicide effect. The candidate mechanisms — inositol depletion via inositol monophosphatase inhibition, GSK-3beta inhibition, neurotrophic and anti-apoptotic signaling — are each supported but none is decisive. The honest position is that lithium's efficacy and its mechanism are decoupled: we use it well without fully understanding it.

Exercises Intermediate+

Exercise 1 (medium, conceptual).

An SSRI raises synaptic serotonin within hours, but depressed patients typically need 4-6 weeks to feel better. State two distinct mechanistic explanations for this delay, and predict what each explanation would imply for a drug that raised serotonin and pre-emptively blocked 5-HT1A autoreceptors.

Hint

One explanation puts the bottleneck at a receptor adaptation (the autoreceptor brake). The other puts it downstream, at slower structural changes such as neurogenesis.

Answer

Explanation A — autoreceptor brake. Acute SSRI dosing activates 5-HT1A somatodendritic autoreceptors, which reduce serotonin neuron firing and offset the reuptake blockade. Over weeks the autoreceptors desensitize, the brake lifts, and effective serotonin signaling rises. Prediction: a drug combining SSRI action with 5-HT1A autoreceptor blockade should act faster, because it skips the desensitization lag.

Explanation B — downstream structural adaptation. The antidepressant effect depends on slow processes such as BDNF upregulation, hippocampal neurogenesis, and reduced neuroinflammation. These take weeks regardless of how fast serotonin rises. Prediction: an SSRI-plus-autoreceptor-blocker would raise serotonin sooner but would not produce correspondingly faster mood improvement, because the structural bottleneck still takes weeks.

The two explanations are not mutually exclusive, and both could operate simultaneously. The prediction that distinguishes them is the onset curve of the combination drug versus a plain SSRI.

Exercise 2 (medium, conceptual).

Why does a partial agonist at the dopamine D2 receptor (such as aripiprazole) behave differently in a dopamine-rich versus a dopamine-poor environment? Explain how this dual behavior is useful in schizophrenia.

Hint

A partial agonist has a ceiling: it can never push receptor activation above its own intrinsic activity. Compare its effect to endogenous dopamine when dopamine is very high versus very low.

Answer

In a dopamine-poor environment (such as the mesocortical pathway in schizophrenia, where negative and cognitive symptoms partly reflect under-stimulation), a partial agonist raises effective receptor activation above what little endogenous dopamine provides, modestly improving signaling. In a dopamine-rich environment (the hyperactive mesolimbic pathway thought to drive positive symptoms), the partial agonist competes with and lowers effective activation, because its ceiling sits below the level excess dopamine would otherwise produce.

The same molecule therefore acts as a functional agonist where the system is underactive and as a functional antagonist where it is overactive. This stabilizing behavior is why aripiprazole can treat positive symptoms while causing less EPS than a pure D2 antagonist and may help negative symptoms more than typicals — though the clinical effect sizes are modest.

Exercise 3 (hard, conceptual).

Ketamine produces antidepressant effects within hours, whereas SSRIs take weeks. One researcher concludes that ketamine has "solved" the slow-onset problem of antidepressants. Critically evaluate this claim, distinguishing the speed of effect from its durability and mechanism, and state what additional evidence you would require before accepting the conclusion.

Hint

Separate three questions: how fast does it act, how long does a single dose last, and through what pathway does it act. Rapid onset does not automatically mean the slow-onset problem is "solved."

Answer

The claim conflates speed with the broader clinical problem. Ketamine's onset is rapid — a single sub-anesthetic dose can lower depression scores within hours, acting via NMDA antagonism, a glutamate surge, and downstream synaptogenesis (BDNF-dependent). This is genuinely different from the SSRI time course and tells us the slow onset of SSRIs is a property of that mechanism, not of antidepressant action in general.

But three caveats weaken the "solved" framing:

Durability. The antidepressant effect of a single ketamine dose often fades within days to two weeks. Repeated dosing is required, and the long-term safety and efficacy of repeated dosing are still being characterized. Esketamine is delivered as a long-term schedule, not a single cure.
Different mechanism, not the same mechanism faster. Ketamine does not accelerate the SSRI pathway; it engages a separate glutamate-based cascade. So the slow-onset problem is bypassed, not solved for the monoamine class.
Side-effect and abuse profile. Ketamine is a dissociative anesthetic with abuse potential, and repeated use carries urological and cognitive concerns. "Solved" requires that the benefits survive chronic use at acceptable cost.

Accepting the conclusion would require randomized evidence of sustained remission over months on a defined regimen, an acceptable long-term safety profile, and a mechanistic account of why the rapid effect is maintained rather than transient. None of those is yet settled.

Competing perspectives: mechanism, placebo, and the meaning of "biological" treatment Master

Acute versus chronic effects and the limits of the monoamine story

The cleanest way to see the inadequacy of the simple monoamine hypothesis is to notice that depleting serotonin does not reliably induce depression in healthy people, and raising it does not reliably relieve depression immediately. If the disorder were simply a serotonin deficit, both manipulations would behave more predictably. The chronic-onset pattern of SSRI benefit, the partial response of many patients, and the rapid but transient action of ketamine together point to a picture in which monoamines are upstream modulators of slower, more fundamental processes: synaptic plasticity, neurogenesis, and neuroinflammation.

The inflammation hypothesis of depression generalizes this. A subset of depressed patients show elevated pro-inflammatory cytokines (CRP, IL-6, TNF-alpha), and anti-cytokine biologics such as ustekinumab show antidepressant effects preferentially in that inflammatory subgroup. The implication is that "depression" is likely several disorders with distinct final common pathways, only one of which runs through monoamines.

The STAR*D trial and the reality of treatment resistance

The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial is the largest practical effectiveness study of antidepressant treatment. Its central finding is sobering: cumulative remission rates were roughly 28-33% at the first level (citalopram) and declined across successive levels of treatment, with diminishing returns at each step. By the later levels, remission rates had fallen below 15%.

STAR*D reframes how "antidepressants work" should be read. For a substantial fraction of patients, sequential monotherapies and combinations do not produce remission. The condition is often chronic and recurrent, and the field's metrics (response versus remission; acute versus maintenance) materially affect how efficacy is reported. Treatment-resistant depression is not a fringe population; it is a large share of the real-world caseload.

Ketamine, esketamine, and the glutamate pivot

Ketamine (and its S-enantiomer esketamine/Spravato) opened the glutamate era of antidepressant research. The mechanism is complex: NMDA receptor antagonism on GABAergic interneurons disinhibits glutamate release, producing a glutamate surge that activates AMPA receptors and triggers mTOR-dependent synaptogenesis in the prefrontal cortex. The result is rapid synapse formation in stress-vulnerable regions, detectable within hours.

The promise is real, and so are the cautions. The single-dose effect often does not persist; relapse within one to two weeks is common; the abuse and dissociative profiles are nontrivial; and the rapid antidepressant mechanism has not yet translated cleanly into a non-psychedelic, non-dissociative drug — rapastinel showed antidepressant signals in early studies but failed in phase 3, a reminder that mechanism stories often break under confirmatory testing.

Psychedelic-assisted therapy: REBUS and the disintegration of the default mode network

The psychedelic renaissance rests on a specific neurobiological hypothesis. Classical psychedelins (psilocybin, LSD, DMT) are 5-HT2A receptor agonists. Robin Carhart-Harris's REBUS model (RElaxed Beliefs Under pSychedelics) argues that 5-HT2A agonism in deep cortical layers temporarily relaxes the precision of high-level prior beliefs, loosening the rigid cognitive and affective patterns that maintain depression, addiction, and trauma.

Imaging studies show that psychedelics produce disintegration and desegregation of the default mode network — the system implicated in self-referential thought and rumination. The therapeutic hypothesis is that the rigid, over-precise self-model that underpins disorders like treatment-resistant depression becomes briefly malleable, and that a structured therapeutic context can guide a reorganization that outlasts the drug session.

The clinical evidence is promising but must be read carefully:

Psilocybin. Griffiths et al. (2016) showed sustained positive changes in mood, behavior, and a measure of "mystical-type experience" in healthy volunteers. Davis et al. (2021, JAMA Psychiatry) found psilocybin-assisted therapy produced large reductions in depression severity, outperforming a low-dose comparator. Cancer-related existential distress and treatment-resistant depression are the leading indications.
MDMA. Distinct from classical psychedelics, MDMA triggers serotonin and dopamine release and oxytocin signaling, producing a prosocial, low-fear state. The MAPS-sponsored phase 3 trials (Mithoefer et al.) report large PTSD remission rates after a small number of sessions paired with structured therapy.
Ayahuasca (DMT plus a monoamine oxidase inhibitor) and ibogaine (investigated for opioid addiction, with cardiotoxicity a serious concern) round out the list, each at an earlier evidence stage.

The methodological caveat for all of these is blinding. Psychedelics produce unmistakable subjective effects, which makes true double-blinding very difficult, and expectancy effects are substantial. Stronger designs (active placebos, low-dose comparators, independent raters) are needed to estimate how much of the effect is pharmacological versus therapeutic-contextual.

Brain stimulation: from ECT to SAINT to DBS

The stimulation landscape has moved in two directions — more focal and more intense.

ECT advances. Right unilateral ultra-brief pulse ECT spares cognition relative to bilateral stimulation while preserving much of the efficacy, the most important refinements of the last two decades. Magnetic seizure therapy (MST), which uses magnetic fields rather than electricity to induce the seizure, achieves greater spatial focality and aims to spare memory further. Ketamine augmentation of ECT is under active study for accelerated response.

TMS advances. The Stanford SAINT / SNT (Stanford Accelerated Intelligent Neuromodulation Therapy / Stanford Neuromodulation Therapy) protocol compresses treatment into five sessions per day for five days. Initial reports cite remission rates near 79%, far above conventional rTMS, although replication and durability data are still accruing. Personalized target selection uses functional connectivity (the Cole approach) to identify the DLPFC node most anticorrelated with the subgenual cingulate — the network signature associated with depression — rather than stimulating a fixed anatomical landmark. Theta burst stimulation delivers the equivalent of a conventional rTMS course in minutes rather than half an hour.

Deep brain stimulation (DBS). Implanted electrodes target the subgenual cingulate (Helen Mayberg), the ventral capsule (Bart Nuttin), and the anterior limb of the internal capsule, for treatment-resistant depression and OCD. The evidence is mixed across targets and patients, and the procedure is reserved for severe, refractory cases. DBS is mechanistically informative even where it is not yet clinically routine: it localizes the circuitry involved.

Pharmacogenomics, adherence, and the pipeline

Pharmacogenomics uses CYP450 genotyping — chiefly CYP2D6 and CYP2C19 — to classify patients as poor, intermediate, extensive, or ultrarapid metabolizers and to adjust dosing accordingly. The clinical value is real but bounded: genotype explains a portion of dose-response variation and some of the worst side-effect surprises, but it does not yet predict which drug a given patient will respond to.

Long-acting injectable antipsychotics address adherence, which is among the strongest predictors of relapse in schizophrenia; depot formulations smooth the daily-pill burden and make non-adherence visible rather than silent.

The drug pipeline has moved beyond monoamines: glutamate modulators, neuroinflammation-targeting agents, the opioid system (naltrexone; the combination ALKS 5461 for depression, which has had a turbulent regulatory path), and orexin antagonists (suvorexant for insomnia). Each represents a bet that the next generation of psychiatric drugs will act on pathways the monoamine era ignored.

Connections Master

Therapy and treatment approaches 29.10.01. The prerequisite unit. The broader taxonomy of treatment modalities is developed there; this unit zooms in on the biological subset and its mechanisms. The history of forced medication and overprescription raised there is the ethical backdrop against which any new biological treatment — including psychedelics and DBS — must be read.
Evidence-based therapies 29.10.02 pending. The sibling unit. The TADS finding (fluoxetine plus CBT outperformed either alone for adolescent depression) and the maintenance-medication comparisons show biological and psychological treatments are complements, not substitutes, for moderate-to-severe disorders. The common-factors debate there has its mirror image here: how much of a drug's effect is specific pharmacology versus the placebo-and-context component?
Psychological disorders 29.09.01. Biological treatments are matched to specific disorders — antipsychotics to psychosis, lithium to bipolar, stimulants to ADHD — and the validity of that matching depends on the validity of the diagnoses themselves. The controversy over diagnostic boundaries raised in the disorders unit propagates directly into prescribing practice.
Neuroscience: brain and behaviour 29.02.01 and neurotransmitter systems 29.02.03 pending. Every mechanism in this unit — receptor binding, the dopaminergic pathways, the default mode network, the glutamatergic cascade — is grounded in the neuroscience strand. The acute-chronic SSRI gap cannot be reasoned about without the receptor and signaling vocabulary developed there.
Neuroplasticity 29.02.04 pending. BDNF upregulation, hippocampal neurogenesis, and ketamine-driven synaptogenesis are the master-level mechanisms that mediate slow antidepressant response. They are precisely the phenomena that unit formalizes.
Introduction and methods 29.01.01. The RCT apparatus, placebo effects, publication bias, and researcher allegiance effects apply directly to the antidepressant and psychedelic trial literature. The STAR*D design and the blinding problem in psychedelic trials are methodological questions, not just clinical ones.
Cross-cultural and indigenous psychology 29.12.01. Psychedelic plants (psilocybin mushrooms, ayahuasca, peyote, iboga) have centuries of Indigenous ceremonial use. The contemporary clinical appropriation of these substances raises the same translation-and-reduction questions raised for mindfulness in the cultural unit: what is gained, and what is lost, when an embedded ceremonial practice is extracted as a pharmacological intervention?

Historical and philosophical context Master

Chlorpromazine and the emptying of the asylums

The modern pharmacological era begins in 1952, when chlorpromazine (Thorazine) was first given to psychiatric patients in Paris. The drug did not cure psychosis, but it calmed agitation and reduced positive symptoms enough that many institutionalized patients could be discharged. Within a decade the population of psychiatric hospitals in Europe and North America began a decline that defined deinstitutionalization. Whether deinstitutionalization was a humanitarian success (people freed from warehouses) or a policy failure (people freed into homelessness and prisons without community support) remains contested, and both readings are partly correct. The drug was the technical precondition for both outcomes.

Lithium: the salt that worked before anyone knew why

John Cade's 1949 observation that lithium quieted manic patients in an Australian hospital is one of the great single-physician discoveries of twentieth-century medicine. Lithium entered practice on the strength of clinical effect, decades before any mechanistic hypothesis was available, and — as noted above — it retains its first-line status despite the absence of a settled mechanism. The case is a standing rebuke to the assumption that effective treatment must follow from understood mechanism. Sometimes the empirical tail wags the mechanistic dog.

The monoamine hypothesis and its slow retirement

The monoamine hypothesis of depression, formulated in the 1960s from the observation that reserpine (which depletes monoamines) induced depression and that the early antidepressants raised monoamines, was the field's organizing story for decades. It is simple, it is falsifiable, and it has been falsified in its strong form: serotonin depletion does not reliably cause depression, and serotonin elevation does not reliably relieve it. What survives is a weaker, more accurate claim: monoamine systems are involved in mood regulation and are one useful pharmacological entry point into disorders whose deeper biology is heterogeneous (glutamatergic, inflammatory, neurotrophic). The history is a case study in how a clean hypothesis can outlive its strong evidence while seeding its own successor.

ECT: stigma, evidence, and the ethics of memory

No psychiatric treatment carries heavier cultural baggage than ECT. The public image — fixed by One Flew Over the Cuckoo's Nest and by the genuinely abusive practices of the pre-anesthesia era — is of punishment, not therapy. The evidence is that modern ECT, delivered under anesthesia with muscle relaxation, is among the most effective treatments in all of psychiatry for severe depression and catatonia.

The tension is real and does not dissolve on inspection. ECT works, and ECT causes memory disruption — particularly retrograde autobiographical memory around the treatment period, more so with bilateral placement. The ethical question is not "is it bad" or "is it good" but under what conditions of consent, severity, and electrode placement the trade is worth it. Refinements such as right unilateral ultra-brief pulse stimulation exist precisely to push that trade in the patient's favor. Dismissing ECT out of hand on the basis of its past is a different kind of error from pretending its past and its side effects do not matter.

The psychedelic renaissance and the question of ceremonial context

The current wave of psychedelic research is sometimes framed as wholly new. It is not. Psilocybin, mescaline, LSD, and ayahuasca have long histories of Indigenous ceremonial use, and the mid-twentieth-century psychiatric investigation of psychedelics (before the 1970 scheduling shutdown in the United States) produced clinical literature that today's trials are rediscovering rather than inventing.

What is new is the imaging and molecular resolution: REBUS, default-mode-network desegregation, and 5-HT2A-mediated plasticity give the field a mechanistic vocabulary the earlier era lacked. What is contested is whether the therapeutic benefit comes primarily from the pharmacology, from the structured therapy that surrounds it, from the expectancy amplified by unmistakable subjective effects, or — most likely — from their interaction. The answer matters because it determines whether the active ingredient can be captured in a pill or whether it is irreducibly a property of a guided experience. The history of mindfulness — extracted from a Buddhist ethical framework and repackaged as a technique — suggests that the same question will be asked of psychedelics, and that the answer will be similarly contested.

Psychiatric drugs and the politics of prescribing

The history of pharmacology is inseparable from the history of prescribing practice, which in turn is inseparable from economics and regulation. The 400% rise in U.S. antidepressant prescribing between the late 1980s and the 2010s far outpaces any plausible rise in depression prevalence. Direct-to-consumer advertising (legal only in the United States and New Zealand), the 15-minute "med check" reimbursement structure, and diagnostic expansion in successive DSM editions together produced a prescribing culture whose scale cannot be explained by the efficacy of the drugs alone. Every new class — ketamine, esketamine, eventually psychedelics — will be absorbed into that culture and shaped by it. The clinical question "does it work?" and the policy question "how should it be used?" are not the same question, and conflating them is the recurring error of both enthusiasts and critics.

Bibliography Master

Stahl, S. M., Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5th ed. (Cambridge University Press, 2021).
Myers, D. G. and DeWall, C. N., Psychology, 13th ed. (Worth Publishers, 2021), Ch. 15.
Gleitman, H., Gross, J., and Reisberg, D., Psychology, 8th ed. (W. W. Norton, 2011), Ch. 15.
Cade, J. F. J., "Lithium Salts in the Treatment of Psychotic Excitement," Medical Journal of Australia 2(10) (1949), 349-352.
Delay, J. and Deniker, P., "Le traitement des psychoses par une methode neurolytique derivee de l'hibernotherapie," Congres des medecins alienistes et neurologistes de France (1952), 497-502.
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al., "Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report," American Journal of Psychiatry 163(11) (2006), 1905-1917.
Trivedi, M. H., Fava, M., Wisniewski, S. R., et al., "Medication Augmentation after the Failure of SSRIs for Depression," New England Journal of Medicine 354(12) (2006), 1243-1252.
Berman, R. M., Cappiello, A., Anand, A., et al., "Antidepressant Effects of Ketamine in Depressed Patients," Biological Psychiatry 47(4) (2000), 351-354.
Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., et al., "A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression," Archives of General Psychiatry 63(8) (2006), 856-864.
Carhart-Harris, R. L. and Friston, K. J., "REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics," Pharmacological Reviews 71(3) (2019), 316-344.
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., et al., "Psilocybin with Psychological Support for Treatment-Resistant Depression: An Open-Label Feasibility Study," Lancet Psychiatry 3(7) (2016), 619-627.
Griffiths, R. R., Johnson, M. W., Carducci, M. A., et al., "Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer: A Randomized Double-Blind Trial," Journal of Psychopharmacology 30(12) (2016), 1181-1197.
Davis, A. K., Barrett, F. S., May, D. G., et al., "Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial," JAMA Psychiatry 78(5) (2021), 481-489.
Mithoefer, M. C., Feduccia, A. A., Jerome, L., et al., "MDMA-Assisted Psychotherapy for Treatment of PTSD: An Enrollee-Blinded Phase 3 RCT," Nature Medicine 29 (2023), 1217-1225.
Cole, E. J., Stimpson, K. H., Bentzley, B. S., et al., "Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression," American Journal of Psychiatry 177(8) (2020), 716-726.
Mayberg, H. S., Lozano, A. M., Voon, V., et al., "Deep Brain Stimulation for Treatment-Resistant Depression," Neuron 45(5) (2005), 651-660.
Krishnan, V. and Nestler, E. J., "The Molecular Neurobiology of Depression," Nature 455 (2008), 894-902.
Duman, R. S. and Aghajanian, G. K., "Synaptic Dysfunction in Depression: Potential Therapeutic Targets," Science 338(6103) (2012), 68-72.
Raison, C. L. and Miller, A. H., "Is Depression an Inflammatory Disorder?," Current Psychiatry Reports 13(6) (2011), 467-475.
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., et al., "Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Clinical Evidence and Implementation," American Journal of Psychiatry 178(5) (2021), 383-399.
Ukai, K., Okazaki, S., Ando, M., et al., (STAR*D reanalysis of cumulative non-remission), BMJ 380 (2023), e072614.
Nutt, D. J., King, L. A., and Phillips, L. D., "Drug Harms in the UK: A Multicriteria Decision Analysis," Lancet 376(9752) (2010), 1558-1565.
Belmaker, R. H. and Agam, G., "Major Depressive Disorder," New England Journal of Medicine 358(1) (2008), 55-68.
Kapur, S. and Mamo, D., "Half a Century of Antipsychotics and Still a Central Role for Dopamine D2 Receptors," Progress in Neuro-Psychopharmacology and Biological Psychiatry 27(7) (2003), 1081-1090.